Perspective Therapeutics (CATX) 10-Q 12 May 22 2022 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Mar. 31, 2022	May 09, 2022
Document Information [Line Items]
Entity Central Index Key	0000728387
Entity Registrant Name	IsoRay, Inc.
Amendment Flag	false
Current Fiscal Year End Date	--06-30
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2022
Document Transition Report	false
Entity File Number	001-33407
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	41-1458152
Entity Address, Address Line One	350 Hills St., Suite 106
Entity Address, City or Town	Richland
Entity Address, State or Province	WA
Entity Address, Postal Zip Code	99354
City Area Code	509
Local Phone Number	375-1202
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	ISR
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		142,040,266

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2022	Jun. 30, 2021
Current assets:
Cash and cash equivalents	$ 58,904,000	$ 63,828,000
Accounts receivable, net	2,140,000	2,013,000
Inventory	1,163,000	980,000
Prepaid expenses and other current assets	551,000	481,000
Total current assets	62,758,000	67,302,000
Property and equipment, net	1,935,000	1,958,000
Right of use asset, net (Note 8)	577,000	768,000
Restricted cash	182,000	182,000
Inventory, non-current	562,000	76,000
Other assets, net	99,000	130,000
Total assets	66,113,000	70,416,000
Current liabilities:
Accounts payable and accrued expenses	769,000	730,000
Lease liability (Note 8)	264,000	252,000
Accrued protocol expense	125,000	98,000
Accrued radioactive waste disposal	94,000	100,000
Accrued payroll and related taxes	448,000	362,000
Accrued vacation	256,000	259,000
Total current liabilities	1,956,000	1,801,000
Non-current liabilities:
Lease liability, non-current (Note 8)	324,000	524,000
Accrued payroll and related taxes, non-current	0	77,000
Asset retirement obligation	632,000	608,000
Total liabilities	2,912,000	3,010,000
Commitments and contingencies (Note 7)
Stockholders' equity:
Preferred stock, $.001 par value; 7,000,000 shares authorized: Series B: 5,000,000 shares allocated; no shares issued and outstanding	0	0
Common stock, $.001 par value; 200,000,000 shares authorized; 142,040,266 and 141,915,266 shares issued and outstanding	142,000	142,000
Additional paid-in capital	159,578,000	158,589,000
Accumulated deficit	(96,519,000)	(91,325,000)
Total stockholders' equity	63,201,000	67,406,000
Series B Preferred Stock [Member]
Stockholders' equity:
Total liabilities and stockholders' equity	$ 66,113,000	$ 70,416,000

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2022	Jun. 30, 2021
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	7,000,000	7,000,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	142,040,266	141,915,266
Common stock, shares outstanding (in shares)	142,040,266	141,915,266
Series B Preferred Stock [Member]
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Sales, net	$ 2,910	$ 2,600	$ 8,290	$ 7,343
Cost of sales	1,469	1,238	4,600	3,568
Gross profit	1,441	1,362	3,690	3,775
Operating expenses:
Research and development	549	362	1,786	959
Sales and marketing	687	581	2,150	1,781
General and administrative	1,581	1,183	5,039	3,379
Loss on equipment disposal	0	2	0	9
Total operating expenses	2,817	2,128	8,975	6,128
Operating loss	(1,376)	(766)	(5,285)	(2,353)
Non-operating income:
Interest income, net	29	21	91	27
Non-operating income	29	21	91	27
Net loss	(1,347)	(745)	(5,194)	(2,326)
Preferred stock dividends	0	0	0	(3)
Net loss applicable to common shareholders	$ (1,347)	$ (745)	$ (5,194)	$ (2,329)
Basic and diluted loss per share (in dollars per share)	$ (0.01)	$ (0.01)	$ (0.04)	$ (0.03)
Weighted average shares used in computing net loss per share:
Basic and diluted (in shares)	142,040	122,566	141,970	91,277

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (5,194)	$ (2,326)
Adjustments to reconcile net loss to net cash used by operating activities:
Depreciation expense	183	107
Loss on equipment disposals	0	10
Amortization of other assets	31	28
Accretion of asset retirement obligation	24	23
Share-based compensation	933	260
Changes in operating assets and liabilities:
Accounts receivable, net	(127)	25
Inventory	(669)	(141)
Prepaid expenses and other current assets	(66)	(57)
Accounts payable and accrued expenses	39	340
Accrued protocol expense	27	80
Accrued radioactive waste disposal	(6)	5
Accrued payroll and related taxes	9	(109)
Accrued vacation	(3)	36
Net cash used by operating activities	(4,819)	(1,719)
CASH FLOWS FROM INVESTING ACTIVITIES:
Additions to property and equipment	(161)	(266)
Proceeds from sale of equipment	0	1
Additions to other assets	0	(7)
Net cash used by investing activities	(161)	(272)
CASH FLOWS FROM FINANCING ACTIVITIES:
Preferred dividends paid	0	(9)
Proceeds from sales of common stock, pursuant to underwritten offering, net	0	56,375
Proceeds from sales of common stock, pursuant to exercise of warrants	0	7,784
Proceeds from sales of common stock, pursuant to exercise of options	56	291
Net cash provided by financing activities	56	64,441
Net increase (decrease) in cash, cash equivalents, and restricted cash	(4,924)	62,450
Cash, cash equivalents, and restricted cash beginning of period	64,010	2,573
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH END OF PERIOD	59,086	65,023
Reconciliation of cash, cash equivalents, and restricted cash to the consolidated balance sheets:
Cash and cash equivalents	58,904	64,841
Restricted cash	182	182
Total cash, cash equivalents, and restricted cash shown on the consolidated statements of cashflows	$ 59,086	$ 65,023

Consolidated Statement of Chang

Consolidated Statement of Changes in Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Preferred Stock [Member]Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balances (in shares) at Jun. 30, 2020	59,065	68,897,779
Balances at Jun. 30, 2020	$ 0	$ 69	$ 93,592	$ (87,938)	$ 5,723
Share-based compensation			85		85
Net loss				(713)	(713)
Balances (in shares) at Sep. 30, 2020	59,065	68,897,779
Balances at Sep. 30, 2020	$ 0	$ 69	93,677	(88,651)	5,095
Balances (in shares) at Jun. 30, 2020	59,065	68,897,779
Balances at Jun. 30, 2020	$ 0	$ 69	93,592	(87,938)	5,723
Net loss					$ (2,326)
Issuance of common stock pursuant to exercise of options (in shares)					520,315
Balances (in shares) at Mar. 31, 2021		141,465,266
Balances at Mar. 31, 2021		$ 141	158,221	(90,264)	$ 68,098
Balances (in shares) at Sep. 30, 2020	59,065	68,897,779
Balances at Sep. 30, 2020	$ 0	$ 69	93,677	(88,651)	5,095
Share-based compensation			81		81
Net loss				(868)	(868)
Conversion of preferred stock to common stock (in shares)	(59,065)	59,065
Issuance of common stock pursuant to underwritten offering, net (in shares)		18,269,230
Issuance of common stock pursuant to underwritten offering, net		$ 18	8,453		8,471
Issuance of common stock pursuant to exercise of options (in shares)		6,250
Issuance of common stock pursuant to exercise of options			3		3
Payment of dividend to preferred stockholders			(9)		(9)
Balances (in shares) at Dec. 31, 2020	0	87,232,324
Balances at Dec. 31, 2020	$ 0	$ 87	102,205	(89,519)	12,773
Share-based compensation			94		94
Net loss				(745)	(745)
Issuance of common stock pursuant to underwritten offering, net (in shares)		41,400,000
Issuance of common stock pursuant to underwritten offering, net		$ 41	47,863		$ 47,904
Issuance of common stock pursuant to exercise of options (in shares)		514,065			514,065
Issuance of common stock pursuant to exercise of options		$ 1	287		$ 288
Issuance of common stock pursuant to exercise of warrants (in shares)		12,318,877
Issuance of common stock pursuant to exercise of warrants		$ 12	7,772		7,784
Balances (in shares) at Mar. 31, 2021		141,465,266
Balances at Mar. 31, 2021		$ 141	158,221	(90,264)	68,098
Balances (in shares) at Jun. 30, 2021	0	141,915,266
Balances at Jun. 30, 2021	$ 0	$ 142	158,589	(91,325)	67,406
Share-based compensation			596		596
Net loss				(2,243)	(2,243)
Balances (in shares) at Sep. 30, 2021	0	141,915,266
Balances at Sep. 30, 2021	$ 0	$ 142	159,185	(93,568)	65,759
Balances (in shares) at Jun. 30, 2021	0	141,915,266
Balances at Jun. 30, 2021	$ 0	$ 142	158,589	(91,325)	67,406
Net loss					$ (5,194)
Issuance of common stock pursuant to exercise of options (in shares)					125,000
Balances (in shares) at Mar. 31, 2022	0	142,040,266
Balances at Mar. 31, 2022	$ 0	$ 142	159,578	(96,519)	$ 63,201
Balances (in shares) at Sep. 30, 2021	0	141,915,266
Balances at Sep. 30, 2021	$ 0	$ 142	159,185	(93,568)	65,759
Share-based compensation			180		180
Net loss				(1,604)	(1,604)
Issuance of common stock pursuant to exercise of options (in shares)		125,000
Issuance of common stock pursuant to exercise of options			56		56
Balances (in shares) at Dec. 31, 2021	0	142,040,266
Balances at Dec. 31, 2021	$ 0	$ 142	159,421	(95,172)	64,391
Share-based compensation			157		157
Net loss				(1,347)	$ (1,347)
Issuance of common stock pursuant to exercise of options (in shares)					0
Balances (in shares) at Mar. 31, 2022	0	142,040,266
Balances at Mar. 31, 2022	$ 0	$ 142	$ 159,578	$ (96,519)	$ 63,201

Note 1 - Basis of Presentation

Note 1 - Basis of Presentation	9 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]	1. Basis of Presentation The accompanying unaudited interim consolidated financial statements are those of Isoray, Inc., and its wholly-owned subsidiaries, referred to herein as “Isoray” or the “Company”. All significant intercompany accounts and transactions have been eliminated in the consolidation. In the opinion of management, all adjustments necessary for the fair statement of the consolidated financial statements have been included. These unaudited interim consolidated financial statements should be read in conjunction with our audited consolidated financial statements and related notes as set forth in the Company’s annual report filed on Form 10 June 30, 2021. The unaudited consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Certain information and note disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (GAAP) have been condensed or omitted pursuant to those rules and regulations, although we believe that the disclosures are adequate for the information not The Company anticipates that as the result of continuing operating losses and the significant net operating losses available from prior fiscal years, its effective income tax rate for fiscal year 2022

Note 2 - New Accounting Standar

Note 2 - New Accounting Standards	9 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Accounting Standards Update and Change in Accounting Principle [Text Block]	2. New Accounting Standards Accounting Standards Updates to Become Effective in Future Periods Accounting standards that have been issued or proposed by the Financial Accounting Standards Board or “FASB” that do not not not not

Note 3 - Loss Per Share

Note 3 - Loss Per Share	9 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Earnings Per Share [Text Block]	3. Loss per Share Basic and diluted earnings (loss) per share are calculated by dividing net income (loss) available to common stockholders by the weighted average number of common shares outstanding and does not 31, 2022 2021, not Securities not 31, 2022 2021, March 31, 2022 2021 Common stock warrants 2,646 2,646 Common stock options 6,926 4,907 Total potential dilutive securities 9,572 7,553

Note 4 - Inventory

Note 4 - Inventory	9 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Inventory Disclosure [Text Block]	4. Inventory Inventory consisted of the following at March 31, 2022 June 30, 2021 ( March 31, June 30, 2022 2021 Raw materials $ 789 $ 645 Work in process 355 286 Finished goods 19 49 Total inventory, current $ 1,163 $ 980 March 31, June 30, 2022 2021 Enriched barium, non-current $ 496 $ - Raw materials, non-current 66 76 Total inventory, non-current $ 562 $ 76 Inventory, non-current represents raw materials that were ordered in quantities to obtain volume cost discounts which based on current and anticipated sales volumes will not August 25, 2017, 130 December 13, 2021, one August 2017 December 31, 2022. June 30, 2021, 894 On September 9, 2021, September 2021 6000 September 2021, 131, nine March 31, 2022, 622 131 March 31, 2022, 3,404 1,040 twelve 2,364 March 31, 2023. 1,040 no third 131 On March 31, 2022, two first 5746.6 second 6310.4 June 30, 2022. 6,000 131. no 131, third 131

Note 5 - Property and Equipment

Note 5 - Property and Equipment	9 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	5. Property and Equipment Property and equipment consisted of the following at March 31, 2022 June 30, 2021 ( March 31, June 30, 2022 2021 Land $ 366 $ 366 Equipment 4,400 4,202 Leasehold improvements 4,143 4,143 Other 1 457 495 Property and equipment 9,366 9,206 Less accumulated depreciation (7,431 ) (7,248 ) Property and equipment, net $ 1,935 $ 1,958 1 not March 31, 2022 June 30, 2021 2017. three five

Note 6 - Share-based Compensati

Note 6 - Share-based Compensation	9 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	6. Share-Based Compensation The weighted average fair value of stock option awards granted and the key assumptions used in the Black-Scholes valuation model to calculate the fair value are as follows: For the Nine Months Ended March 31, 2022 2021 Weighted average fair value $0.58 $1.03 Options issued 3,064,100 165,000 Exercise price $0.49 to $0.79 $0.64 to $1.66 Expected term (in years) 5 5 Risk-free rate 0.73% to 1.33% 0.22% to 0.57% Volatility 99% 83% to 98% The following table presents the share-based compensation expense recognized for stock-based options during the three 31, 2022 2021 Three Months 2022 2021 Cost of sales $ 12 $ 2 Research and development expenses 33 55 Sales and marketing expenses (18 ) (14 ) General and administrative expenses 130 51 Total share-based compensation $ 157 $ 94 The following table presents the share-based compensation expense recognized for stock-based options during the nine March 31, 2022 2021 Nine Months 2022 2021 Cost of sales $ 68 $ 7 Research and development expenses 204 79 Sales and marketing expenses 46 20 General and administrative expenses 615 154 Total share-based compensation $ 933 $ 260 As of March 31, 2022, 1 .05 A summary of stock options within the Company’s share-based compensation plans as of March 31, 2022 Weighted Weighted Average Number of Exercise Contractual Intrinsic As of March 31, 2022 Options Price Term (Years) Value Outstanding 6,926 $ .72 7.55 $ - Vested and expected to vest 6,926 $ .72 7.55 $ - Vested and exercisable 4,041 $ .69 6.51 $ - There were no options exercised and 514,065 options exercised, with approximately $0 and $652,000 of intrinsic value associated with these exercises, during the three March 31, 2022 2021, There were no option awards granted and 125,000 option awards granted with a fair value of approximately $0 and $152,000, during the three March 31, 2022 2021, There were 84,075 and 2,000 stock option awards which expired during the three March 31, 2022 2021, There were 257,475 and 234,375 stock option awards forfeited during the three March 31, 2022 2021, There were 125,000 and 520,315 stock options exercised, with approximately $3,000 and $653,000 of intrinsic value associated with these exercises, during the nine March 31, 2022 2021, There were 3,064,100 and 165,000 option awards granted with a fair value of approximately $1,763,000 and $170,000 during the nine March 31, 2022 2021, There were 113,575 and 4,000 stock option awards which expired during the nine March 31, 2022 2021, There were 413,700 and 237,500 stock option awards forfeited during the nine March 31, 2022 2021,

Note 7 - Commitments and Contin

Note 7 - Commitments and Contingencies	9 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	7. Commitments and Contingencies Isotope Purchase Agreement On August 26, 2020, August 2020 December 2021 131 February 10, 2021, March 18, 2021, 131 March 18, 2021 March 31, 2023. July 29, 2021, 131 August 19, 2021, 131 April 11, 2022, 131 April 11, 2022, 131.

Note 8 - Leases

Note 8 - Leases	9 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	8. Leases For the three March 31, 2022 2021 three March 31, 2022 2021 For the nine March 31, 2022 2021 nine March 31, 2022 2021 March 31, 2022 The following table presents the future operating lease payments and lease liability included on the consolidated balance sheet related to the Company’s operating lease as of March 31, 2022 ( Year Ending June 30, 2022 (remaining three months) 73 2023 292 2024 264 Total 629 Less: imputed interest (41 ) Total lease liability 588 Less current portion (264 ) Non-current lease liability $ 324

Note 9 - Contracts With Custome

Note 9 - Contracts With Customers	9 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	9. Contracts with Customers Sources of Revenue We have identified the following revenues disaggregated by revenue source: 1. Domestic – direct sales of products and services. 2. International – direct sales of products and services. During the three March 31, 2022 2021, three March 31, 2022, not three March 31, 2021. During the nine March 31, 2022 2021, no nine March 31, 2022, nine March 31, 2021. Concentration of Customers The following are the Company's top customers, facilities, or physician practices that utilize multiple surgical facilities shown as a percentage of total sales: Nine Months Ended March 31, Facilities and Customers 2022 % of total revenue 2021 % of total revenue El Camino, Los Gatos, & other facilities 26.9 % 25.6 % GT Medical Technologies 13.4 % <10.0 % As of March 31, 2022, June 30, 2021,

Note 3 - Loss Per Share (Tables

Note 3 - Loss Per Share (Tables)	9 Months Ended
	Mar. 31, 2022
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	March 31, 2022 2021 Common stock warrants 2,646 2,646 Common stock options 6,926 4,907 Total potential dilutive securities 9,572 7,553

Note 4 - Inventory (Tables)

Note 4 - Inventory (Tables)	9 Months Ended
	Mar. 31, 2022
Notes Tables
Schedule of Inventory, Current [Table Text Block]	March 31, June 30, 2022 2021 Raw materials $ 789 $ 645 Work in process 355 286 Finished goods 19 49 Total inventory, current $ 1,163 $ 980
Schedule of Inventory, Noncurrent [Table Text Block]	March 31, June 30, 2022 2021 Enriched barium, non-current $ 496 $ - Raw materials, non-current 66 76 Total inventory, non-current $ 562 $ 76

Note 5 - Property and Equipme_2

Note 5 - Property and Equipment (Tables)	9 Months Ended
	Mar. 31, 2022
Notes Tables
Property, Plant and Equipment [Table Text Block]	March 31, June 30, 2022 2021 Land $ 366 $ 366 Equipment 4,400 4,202 Leasehold improvements 4,143 4,143 Other 1 457 495 Property and equipment 9,366 9,206 Less accumulated depreciation (7,431 ) (7,248 ) Property and equipment, net $ 1,935 $ 1,958

Note 6 - Share-based Compensa_2

Note 6 - Share-based Compensation (Tables)	9 Months Ended
	Mar. 31, 2022
Notes Tables
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	For the Nine Months Ended March 31, 2022 2021 Weighted average fair value $0.58 $1.03 Options issued 3,064,100 165,000 Exercise price $0.49 to $0.79 $0.64 to $1.66 Expected term (in years) 5 5 Risk-free rate 0.73% to 1.33% 0.22% to 0.57% Volatility 99% 83% to 98%
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months 2022 2021 Cost of sales $ 12 $ 2 Research and development expenses 33 55 Sales and marketing expenses (18 ) (14 ) General and administrative expenses 130 51 Total share-based compensation $ 157 $ 94 Nine Months 2022 2021 Cost of sales $ 68 $ 7 Research and development expenses 204 79 Sales and marketing expenses 46 20 General and administrative expenses 615 154 Total share-based compensation $ 933 $ 260
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block]	Weighted Weighted Average Number of Exercise Contractual Intrinsic As of March 31, 2022 Options Price Term (Years) Value Outstanding 6,926 $ .72 7.55 $ - Vested and expected to vest 6,926 $ .72 7.55 $ - Vested and exercisable 4,041 $ .69 6.51 $ -

Note 8 - Leases (Tables)

Note 8 - Leases (Tables)	9 Months Ended
	Mar. 31, 2022
Notes Tables
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Year Ending June 30, 2022 (remaining three months) 73 2023 292 2024 264 Total 629 Less: imputed interest (41 ) Total lease liability 588 Less current portion (264 ) Non-current lease liability $ 324

Note 9 - Contracts With Custo_2

Note 9 - Contracts With Customers (Tables)	9 Months Ended
	Mar. 31, 2022
Notes Tables
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	Nine Months Ended March 31, Facilities and Customers 2022 % of total revenue 2021 % of total revenue El Camino, Los Gatos, & other facilities 26.9 % 25.6 % GT Medical Technologies 13.4 % <10.0 %

Note 1 - Basis of Presentation

Note 1 - Basis of Presentation (Details Textual) Pure in Thousands	9 Months Ended
	Mar. 31, 2022
Effective Income Tax Rate Reconciliation, Percent, Total	0.00%

Note 3 - Loss Per Share - Antid

Note 3 - Loss Per Share - Antidilutive Securities (Details) - shares shares in Thousands	9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Antidilutive securities (in shares)	9,572	7,553
Warrant [Member]
Antidilutive securities (in shares)	2,646	2,646
Share-Based Payment Arrangement, Option [Member]
Antidilutive securities (in shares)	6,926	4,907

Note 4 - Inventory (Details Tex

Note 4 - Inventory (Details Textual) - Enriched Barium Inventory [Member] - USD ($)	Sep. 09, 2021	Mar. 31, 2022
Payments to Suppliers	$ 720,000
Purchase Agreement One [Member]
Agreements, Payable to Suppliers		$ 876,357
Purchase Agreement Two [Member]
Agreements, Payable to Suppliers		$ 957,608

Note 4 - Inventory - Current In

Note 4 - Inventory - Current Inventory (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Jun. 30, 2021
Raw materials	$ 789	$ 645
Work in process	355	286
Finished goods	19	49
Total inventory, current	$ 1,163	$ 980

Note 4 - Inventory - Noncurrent

Note 4 - Inventory - Noncurrent Inventory (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Jun. 30, 2021
Total inventory, non-current	$ 562	$ 76
Enriched Barium Inventory [Member]
Total inventory, non-current	496	0
Raw Materials [Member]
Total inventory, non-current	$ 66	$ 76

Note 5 - Property and Equipme_3

Note 5 - Property and Equipment (Details Textual) - USD ($)	9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Jun. 30, 2021
Depreciation, Total	$ 183,000	$ 107,000
Other [Member]
Depreciation, Total	$ 0
Construction in Progress [Member]
Capitalized Costs Related to Advance Planning and Design Work			$ 207,000

Note 5 - Property and Equipme_4

Note 5 - Property and Equipment - Summary of Property and Equipment (Details) - USD ($) $ in Thousands		Mar. 31, 2022	Jun. 30, 2021
Property and equipment, gross		$ 9,366	$ 9,206
Less accumulated depreciation		(7,431)	(7,248)
Property and equipment, net		1,935	1,958
Land [Member]
Property and equipment, gross		366	366
Equipment [Member]
Property and equipment, gross		4,400	4,202
Leasehold Improvements [Member]
Property and equipment, gross		4,143	4,143
Other [Member]
Property and equipment, gross	[1]	$ 457	$ 495
[1]	Plant and equipment, not placed in service are items that meet the capitalization threshold or which management believes will meet the threshold at the time of completion and which have yet to be placed into service as of the date of the balance sheet, and therefore, no depreciation expense has been recognized. Also included at September 30, 2021 and June 30, 2021 are costs associated with advance planning and design work on the Company’s new production facility of approximately $207,000. The advance planning and design work was primarily incurred in fiscal year 2017. The new production facility is currently on hold as the Company has sufficient production capacity to meet future demands and while the Company focuses its resources on revenue growth. It is anticipated that the Company will continue work on the new production facility in the next three to five years.

Note 6 - Share-based Compensa_3

Note 6 - Share-based Compensation (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total	$ 1,113,000		$ 1,113,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)			1 year 18 days
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)	0	514,065	125,000	520,315
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value	$ 0	$ 652,000	$ 3,000	$ 653,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)	0	125,000	3,064,100	165,000
Share-based Compensation Arrangement By Share-based Payment Award Options Grants in Period Fair Value	$ 0	$ 152,000	$ 1,763,000	$ 170,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period (in shares)	84,075	2,000	113,575	4,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period (in shares)	257,475	234,375	413,700	237,500

Note 6 - Share-based Compensa_4

Note 6 - Share-based Compensation - Assumptions (Details) - $ / shares	9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Weighted average fair value (in dollars per share)	$ 0.58	$ 1.03
Options issued (in shares)	3,064,100	165,000
Expected term (in years) (Year)	5 years	5 years
Volatility	99.00%
Minimum [Member]
Exercise price (in dollars per share)	$ 0.49	$ 0.64
Risk-free rate	0.73%	0.22%
Volatility		83.00%
Maximum [Member]
Exercise price (in dollars per share)	$ 0.79	$ 1.66
Risk-free rate	1.33%	0.57%
Volatility		98.00%

Note 6 - Share-based Compensa_5

Note 6 - Share-based Compensation - Share-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Share-based compensation	$ 157	$ 94	$ 933	$ 260
Cost of Sales [Member]
Share-based compensation	12	2	68	7
Research and Development Expense [Member]
Share-based compensation	33	55	204	79
Selling and Marketing Expense [Member]
Share-based compensation	(18)	(14)	46	20
General and Administrative Expense [Member]
Share-based compensation	$ 130	$ 51	$ 615	$ 154

Note 6 - Share-based Compensa_6

Note 6 - Share-based Compensation - Summary of Stock Options (Details) $ / shares in Units, shares in Thousands, $ in Thousands	9 Months Ended
	Mar. 31, 2022USD ($)$ / sharesshares
Outstanding (in shares) | shares	6,926
Outstanding, weighted exercise price (in dollars per share) | $ / shares	$ 0.72
Outstanding, weighted average contractual term (Year)	7 years 6 months 18 days
Outstanding, intrinsic value | $	$ 0
Vested and expected to vest, Options (in shares) | shares	6,926
Vested and expected to vest, weighted exercise price (in dollars per share) | $ / shares	$ 0.72
Vested and expected to vest, weighted average contractual term (Year)	7 years 6 months 18 days
Vested and expected to vest, intrinsic value | $	$ 0
Vested and exercisable (in shares) | shares	4,041
Vested and exercisable, weighted exercise price (in dollars per share) | $ / shares	$ 69
Vested and exercisable, weighted average contractual term (Year)	6 years 6 months 3 days
Vested and exercisable, intrinsic value | $	$ 0

Note 8 - Leases (Details Textua

Note 8 - Leases (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Operating Lease, Expense	$ 78,000	$ 75,000	$ 235,000	$ 227,000
Operating Lease, Weighted Average Remaining Lease Term (Year)	2 years 1 month 6 days		2 years 1 month 6 days
Operating Lease, Weighted Average Discount Rate, Percent	6.00%		6.00%
Cost of Sales [Member]
Operating Lease, Expense	$ 49,000	48,000	$ 148,000	146,000
General and Administrative Expense [Member]
Operating Lease, Expense	$ 29,000	$ 27,000	$ 87,000	$ 81,000

Note 8 - Leases - Future Operat

Note 8 - Leases - Future Operating Lease Payments and Lease Liability (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Jun. 30, 2021
2022 (remaining three months)	$ 73
2023	292
2024	264
Total	629
Less: imputed interest	(41)
Total lease liability	588
Less current portion	(264)	$ (252)
Non-current lease liability	$ 324	$ 524

Note 9 - Contracts With Custo_3

Note 9 - Contracts With Customers (Details Textual) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Mar. 31, 2022USD ($)	Mar. 31, 2021USD ($)	Mar. 31, 2022USD ($)	Mar. 31, 2021	Jun. 30, 2021
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | GT Medical Technologies, Inc. [Member]
Concentration Risk, Percentage			13.40%
Accounts Receivable [Member] | Customer Concentration Risk [Member]
Number of Major Customers			1		1
Accounts Receivable [Member] | Customer Concentration Risk [Member] | El Camino [Member]
Concentration Risk, Percentage			12.90%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | GT Medical Technologies, Inc. [Member]
Concentration Risk, Percentage					10.20%
Prostate Brachytherapy [Member] | Revenue Benchmark [Member] | Product Concentration Risk [Member]
Concentration Risk, Percentage	75.00%	78.00%	76.00%	79.00%
Product and Service, Other [Member] | Revenue Benchmark [Member] | Product Concentration Risk [Member]
Concentration Risk, Percentage	25.00%	22.00%	24.00%	21.00%
Geographic Distribution, Foreign [Member]
Revenue from Contract with Customer, Excluding Assessed Tax	$ 0	$ 0	$ 0

Note 9 - Contracts With Custo_4

Note 9 - Contracts With Customers - Concentration of Customers (Details) - Revenue Benchmark [Member] - Customer Concentration Risk [Member]	9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
El Camino, Los Gatos, & Other Facilities [Member]
Concentration risk	26.90%	25.60%
GT Medical Technologies, Inc. [Member]
Concentration risk	13.40%